In the B16-F10 subcutaneous melanoma model, topical application of exogenous pregnenolone at the primary tumor site was sufficient to compensate for the Cyp11a1 deficiency, restoring tumor growth to levels comparable with control mice (Fig. 5c). The gene discussed is CYP11A1; the disease is melanoma.